Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observation Study

Set Your Location to See Relevant Information

Setting your location helps us to show you nearby providers and locations based on your healthcare needs.

Clinical Trials Details

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observation Study

Study Details

This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.

Learn More

ClinicalTrials.gov NCT number
NCT04871542

Principal Investigators

  • Salvatore Del Prete, MD
Sponsor(s)
Southwest Oncology Group
Contact
Ed Hatton, RN at 203-358-8879
or officeofresearch@stamhealth.org

Location

  • Bennett Cancer Center
    One Hospital Plaza
    Stamford, CT 06902
    Main: 203-276-2695

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.